Come join others currently navigating treatment in our weekly Zoom Meetup! Register here: Tuesdays, 1pm ET.
Fill Out Your Profile to share more about you. Learn more...
Take Our Poll: How well do you feel your family understands your diagnosis?
Podcast: AIs vs. Tamoxifen for Pre-Menopausal Early-Stage, HR+
Options
moderators
Posts: 7,911
December 13, 2021
Dr. Jeremy Braybrooke, is a consultant medical oncologist and clinical lead for oncology at University Hospitals Bristol, as well as a senior clinical research fellow at the University of Oxford. Rosie Bradley is a medical statistician in the Clinical Trial Service Unit at the University of Oxford.
At the 2021 San Antonio Breast Cancer Symposium, Rosie presented the results of their meta-analysis of four studies looking at effectiveness of aromatase inhibitors compared to tamoxifen in pre-menopausal women diagnosed with early-stage, hormone receptor-positive disease.
Listen to the episode to hear them explain:
- the results of the study, showing that an aromatase inhibitor and ovarian suppression reduced recurrence risk more than tamoxifen, but didn't lead to better overall survival
- the side effects of aromatase inhibitors and tamoxifen
- how Dr. Braybrooke is advising his pre-menopausal patients diagnosed with early-stage, hormone receptor-positive disease
Running time: 14:19
Listen now or read the transcript.0
Categories
Join Us on Zoom: Upcoming virtual meetups. Read more...
Give your account some personality! Add a profile photo.